Melanoma & Skin Cancer | Specialty

Surgical Oncology Is More Than Just Surgery

October 25th 2020

After 15 years as a surgeon, Jeffrey M. Farma, MD, says he's still learning how to treat patients with cancer. As fellowship director of the Complex General Surgical Oncology Fellowship at Fox Chase Cancer Center, he expects his trainees to be prepared to do the same.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Immune Checkpoint Inhibition in Stage IV Melanoma

October 12th 2020

Triple Therapy for the Management of Melanoma

October 12th 2020

COMBI-i Trial Data Updates

October 12th 2020

Ipilimumab Dosing Significance in Adjuvant Setting

October 12th 2020

KEYNOTE-054 and CheckMate 238 Trial Updates

October 12th 2020

Checkpoint Blockade Trial Data Updates

October 12th 2020

COMBI-AD Trial 5-Year Analysis Data

October 12th 2020

Molecular Testing in Stage III Melanoma

October 12th 2020

Rapisuwon Reviews Management Approaches for Advanced Noncutaneous Melanoma Subtypes

October 8th 2020

Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.

Sequencing Debate for Frontline BRAF-Mutant Melanoma in Full Force

October 8th 2020

Geoffrey T. Gibney, MD, provides an update on the evolution of frontline treatment in metastatic melanoma.

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

October 7th 2020

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

Adjuvant Nivolumab/Ipilimumab Fails to Significantly Improve RFS in High-Risk Melanoma

October 5th 2020

The immunotherapy combination of adjuvant nivolumab and ipilimumab failed to lead to a statistically significant improvement in recurrence-free survival in the intent-to-treat population of patients with resected stage IIIB/C/D or stage IV melanoma.

Neoadjuvant, Adjuvant Data Provide Evidence of Curative Potential in Advanced Melanoma

October 1st 2020

Michael B. Atkins, MD, discusses the clinical impact of key adjuvant and neoadjuvant data in the melanoma space, as well as the risks and benefits of both approaches.

Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma

September 30th 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses ​the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

September 30th 2020

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ​evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

September 24th 2020

Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.

Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

September 22nd 2020

Alexander N. Shoushtari, MD, discusses the design of the ​phase 3 CheckMate-067 trial in advanced melanoma. 

Spartalizumab/Dabrafenib Misses PFS End Point in Melanoma

September 19th 2020

Spartalizumab plus dabrafenib did not significantly improve progression-free survival over dabrafenib/trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma.